Shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) saw strong trading volume on Thursday . 32,296,889 shares traded hands during trading, an increase of 26% from the previous session’s volume of 25,730,472 shares.The stock last traded at $23.09 and had previously closed at $23.06.

Several analysts recently weighed in on the company. Guggenheim restated a “buy” rating and set a $55.00 target price (down previously from $145.00) on shares of Valeant Pharmaceuticals International in a research note on Saturday, March 19th. Rodman & Renshaw restated a “buy” rating on shares of Valeant Pharmaceuticals International in a research note on Sunday, April 3rd. Wells Fargo & Co. restated a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Saturday, April 9th. BMO Capital Markets restated a “positive” rating on shares of Valeant Pharmaceuticals International in a research note on Friday, April 29th. Finally, Piper Jaffray Cos. restated a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Sunday, May 29th. Seven investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $74.71.

The stock’s 50 day moving average price is $24.10 and its 200-day moving average price is $52.43. The company’s market cap is $7.98 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its quarterly earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 EPS for the quarter, missing the Zacks’ consensus estimate of $1.37 by $0.10. The business had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.34 billion. The company’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.36 earnings per share. On average, analysts expect that Valeant Pharmaceuticals International Inc. will post $6.62 EPS for the current year.

In other news, CEO Joseph C. Papa purchased 202,000 shares of the business’s stock in a transaction on Friday, June 10th. The shares were acquired at an average price of $24.48 per share, with a total value of $4,944,960.00. Following the completion of the transaction, the chief executive officer now owns 2,442,199 shares of the company’s stock, valued at approximately $59,785,031.52. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Other hedge funds have recently modified their holdings of the company. Oppenheimer & Co. Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 51.2% in the fourth quarter. Oppenheimer & Co. Inc. now owns 10,455 shares of the specialty pharmaceutical company’s stock worth $1,062,000 after buying an additional 3,541 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 95.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 127,715 shares of the specialty pharmaceutical company’s stock worth $12,982,000 after buying an additional 62,361 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Valeant Pharmaceuticals International by 64.4% in the fourth quarter. New York State Common Retirement Fund now owns 276,226 shares of the specialty pharmaceutical company’s stock worth $28,078,000 after buying an additional 108,175 shares during the period. Academy Capital Management Inc. TX purchased a new stake in shares of Valeant Pharmaceuticals International during the fourth quarter worth approximately $7,102,000. Finally, OppenheimerFunds Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 14.1% in the fourth quarter. OppenheimerFunds Inc. now owns 611,772 shares of the specialty pharmaceutical company’s stock worth $62,186,000 after buying an additional 75,705 shares during the period.

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.